As T2DM patients exhibit relative resistance to the actions of GIP [91], the main goals of DPP-4 inhibitors are to prolong the beneficial effects of endogenous GLP-1 [92] in order to maintain its insulinotropic activity [93]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.